The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab to treat adults with bullous pemphigoid.
Bullous pemphigoid (BP), which has no FDA-approved targeted therapies, leads to reddening of the skin and the formation of ...
The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults ... and rashes to form on the skin. These lesions are prone to infection as they ...
Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...
The blisters and rash can form over much of the body and ... including chronic pruritus of unknown origin, bullous pemphigoid, and lichen simplex chronicus. These potential uses of dupilumab ...
Sanofi and Regeneron’s Dupixent (dupilumab) has been accepted for priority review by the US Food and Drug Administration (FDA ...
Paris: Sanofi and CD&R have announced that they have signed the share purchase agreement in relation to the sale of a 50 ...
Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to ...
Bullous pemphigoid is a chronic, relapsing skin disease with underlying type 2 inflammation. It is characterized by intense itching, blisters, skin reddening, and painful lesions. Dupilumab is ...
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...
The blisters and rash can form over much of the body and ... including chronic pruritus of unknown origin, bullous pemphigoid, and lichen simplex chronicus. These potential uses of dupilumab ...